The direct detection of neutralino dark matter is analysed in general supergravity scenarios, where non-universal soft scalar and gaugino masses can be present. In particular, the theoretical predictions for the neutralino-nucleon cross section are studied and compared with the sensitivity of dark matter detectors. We take into account the most recent astrophysical and experimental constraints on the parameter space, including the current limit on B(B 0 s → µ + µ − ). The latter puts severe limitations on the dark matter scattering cross section, ruling out most of the regions that would be within the reach of present experiments. We show how this constraint can be softened with the help of appropriate choices of non-universal parameters which increase the Higgsino composition of the lightest neutralino and minimise the chargino contribution to the b → s transition.
Neutralinosχ 0 in supersymmetric theories, the spin-1/2 Majorana-type superpartners of the U(1) and SU(2) neutral electroweak gauge bosons and SU(2) neutral Higgs bosons, are expected to be among light supersymmetric particles so that they can be produced copiously via direct pair production and/or from cascade decays of other sparticles such as sleptons at the planned Large Hadron Collider and the prospective International Linear Collider. Considering the prospects of having both highly polarized neutralinos and possibility of reconstructing their decay rest frames, we provide a systematic investigation of the three-body leptonic decays of the neutralinos in the minimal supersymmetric standard model and demonstrate alternative ways for probing the Majorana nature of the neutralinos and CP violation in the neutralino system.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.